Press Releases

Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

February 23, 2022

Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy

February 22, 2022

Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium

February 17, 2022

Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022

February 9, 2022

Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen

January 10, 2022

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

December 20, 2021

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

December 13, 2021

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021

November 9, 2021

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting

November 9, 2021

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

November 3, 2021